Chiasma (NASDAQ:CHMA) is set to announce its earnings results after the market closes on Wednesday, March 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Shares of Chiasma (NASDAQ:CHMA) opened at $1.60 on Monday. Chiasma has a twelve month low of $1.25 and a twelve month high of $2.95. The company has a market capitalization of $39.01, a price-to-earnings ratio of -1.37 and a beta of 1.06.
Separately, ValuEngine raised Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.